Intrathoracic Impedance Monitoring, Audible Patient Alerts, and Outcome in Patients With Heart Failure

Dirk J. van Veldhuisen*, Frieder Braunschweig, Viviane M. Conraads, Ian Ford, Martin R. Cowie, Guillaume Jondeau, Josef Kautzner, Roberto Munoz Aguilera, Maurizio Lunati, Cheuk Man Yu, Bart Gerritse, Martin Borggrefe

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Heart failure is associated with frequent hospitalizations, often resulting from volume overload. Measurement of intrathoracic impedance with an implanted device with an audible patient alert may detect increases in pulmonary fluid retention early. We hypothesized that early intervention could prevent hospitalizations and affect outcome.We studied 335 patients with chronic heart failure who had undergone implantation of an implantable cardioverter-defibrillator alone (18%) or with cardiac resynchronization therapy (82%). All devices featured a monitoring tool to track changes in intrathoracic impedance (OptiVol) and other diagnostic parameters. Patients were randomized to have information available to physicians and patients as an audible alert in case of preset threshold crossings (access arm) or not (control arm). The primary end point was a composite of all-cause mortality and heart failure hospitalizations. During 14.9?5.4 months, this occurred in 48 patients (29%) in the access arm and in 33 patients (20%) in the control arm (P=0.063; hazard ratio, 1.52; 95% confidence interval, 0.97-2.37). This was due mainly to more heart failure hospitalizations (hazard ratio, 1.79; 95% confidence interval, 1.08-2.95; P=0.022), whereas the number of deaths was comparable (19 versus 15; P=0.54). The number of outpatient visits was higher in the access arm (250 versus 84; P
Original languageEnglish
Pages (from-to)1719-U82
Issue number16
Publication statusPublished - 18 Oct 2011


  • cardiography, impedance
  • devices
  • heart failure
  • outcome assessment
  • randomized controlled trial

Cite this